Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ProImmune Introduces ProStorm™ In Vitro Assay Service

Published: Wednesday, September 19, 2012
Last Updated: Wednesday, September 19, 2012
Bookmark and Share
New service will enable drug developers to identify a potential risk of cytokine storm reactions for new therapeutics.

ProImmune Ltd. has announced the commercial launch of ProStorm™, an in vitro cytokine release assay, which can help assess the likelihood of first infusion reactions to novel therapeutics.

ProStorm™ offers drug developers an improved route to risk identification prior to initiating clinical trials in man.

Cytokine release syndrome (“cytokine storm”) is an acute immune reaction to first infusion of a drug, characterized by immediate release of proinflammatory cytokines.

A lack of understanding of the risk of this reaction contributed to a near-fatal cytokine storm in participants in phase I clinical trials of TGN1412.

There is a clear need for preclinical assays such as ProStorm™ to assess the likelihood of this syndrome occurring.

If a potential risk is indicated, lower doses of the therapeutic can be used alongside prophylactic antihistamines or steroids to mitigate that risk.

ProStorm™ is designed specifically to indicate when a cytokine storm first infusion reaction may be a risk for a drug.

The ProStorm™ assay uses fresh undiluted whole blood from a large cohort of donors, to give a sensitive evaluation of cytokine responses to a therapeutic in one simple step.

Dr. Nikolai Schwabe, CEO of ProImmune, said “First infusion cytokine storm reactions to new therapeutics can represent a substantial stumbling block to drug development. Now, using the ProStorm™ assay service, developers of biologics can gain valuable information to inform the design of their first-in-man trials. By offering ProStorm™, we at ProImmune are extending the range of services we offer to help our clients bring safe and effective therapeutics to market.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!